Steven Ditto, MD
Family Medicine · del City, OKNPI 1568455772
Payments from drug & device makers
Across 272 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$940
- AbbVie$689
- GSK$687
- Pfizer$476
- Novo Nordisk$246
- Abbott$213
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $940 |
| AbbVie(2 entities) | 29 | $689 |
| GSK | 44 | $687 |
| Pfizer | 30 | $476 |
| Novo Nordisk | 15 | $246 |
| Abbott | 11 | $213 |
| Boehringer Ingelheim | 11 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $131 |
| Sumitomo Pharma America, Inc. | 6 | $122 |
| Supernus Pharmaceuticals, Inc. | 5 | $108 |
| Bayer | 6 | $106 |
| Lilly USA, LLC | 6 | $104 |
| Merck | 7 | $103 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Novartis | 4 | $78 |
| Exact Sciences | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Sanofi Pasteur Inc. | 2 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Amgen | 2 | $40 |
| UCB, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Averitas Pharma Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$4,919 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $158,537 |
| JardianceEmpagliflozin | 45 | $61,204 |
| TrulicityDulaglutide | 28 | $47,070 |
| EliquisApixaban | 45 | $37,369 |
| JanuviaSitagliptin Phosphate | 33 | $32,672 |
| LinzessLinaclotide | 34 | $25,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,500 |
| FarxigaDapagliflozin Propanediol | 13 | $20,990 |
| GemtesaVibegron | 14 | $18,623 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $16,565 |
| TradjentaLinagliptin | 15 | $12,519 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $11,152 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $10,378 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,582 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $8,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $246 | $158,537126 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $202 | $84,87671 claims |
| Lilly USA, LLCTrulicity | $104 | $47,07028 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $940 | $42,20258 claims |
| PfizerEliquis | $476 | $37,36945 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $687 | $33,08242 claims |
| MerckJanuvia | $103 | $32,67233 claims |
| AbbVieLinzess | $689 | $25,68534 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $122 | $18,62314 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $85 | $10,37814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in del City
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.